First Department of Oncological Gynaecology and Gynaecology.
Independent Laboratory of Cancer Diagnostics and Immunology, First Department of Oncological Gynaecology and Gynaecology.
Appl Immunohistochem Mol Morphol. 2022 Aug 1;30(7):509-516. doi: 10.1097/PAI.0000000000001046. Epub 2022 Jul 4.
Luteinizing hormone-releasing hormone receptor (LHRHR) expression has been reported in various cancers, including endometrial neoplasms. Thus, LHRHR provides a potential point for therapeutic approach using LHRH analogs as carrier molecules for chemotherapeutic agents in this cancer population. However, clinical data did not prove any potential benefits for patients. We decided to assess LHRHR expression in patients with endometrial cancer to explain possible lack of efficacy in previous clinical reports. LHRHR expression was assessed immunohistochemically in different anatomic and histogenetic compartments of female genital tract of patients with endometrial cancer. The study sample consisted of paraffin tissue blocks obtained from patients who has undergone primary surgery owing to endometrial cancer. Strong LHRHR expression was found in endometrial cancer, fallopian tube, and concurrent atypical hyperplasia. Interestingly, LHRHR expression showed significant differences depending on the respective compartment of the ovary analyzed. Level of LHRHR expression in patients with primary advanced and unresectable disease, particularly in certain ovarian compartments may be substantially lower, which may influence the use of new targeted therapy regimens. The studies on secondary Müllerian system compartment and its hormonal receptor status may be crucial to understand mechanisms of lack of efficacy of LHRH hybrid molecules anti-cancer treatment.
黄体生成素释放激素受体 (LHRHR) 在各种癌症中已有报道，包括子宫内膜肿瘤。因此，LHRHR 为治疗提供了一个潜在的靶点，可使用 LHRH 类似物作为化学治疗剂在该癌症患者群体中的载体分子。然而，临床数据并未证明患者有任何潜在获益。我们决定评估子宫内膜癌患者中 LHRHR 的表达，以解释以前临床报告中缺乏疗效的原因。LHRHR 的表达通过免疫组织化学方法在子宫内膜癌患者的女性生殖道不同解剖和组织发生部位进行评估。研究样本由因子宫内膜癌而接受初次手术的患者的石蜡组织块组成。在子宫内膜癌、输卵管和同时存在的非典型增生中发现了强烈的 LHRHR 表达。有趣的是，LHRHR 的表达根据所分析的卵巢各自部位显示出显著差异。原发性晚期和不可切除疾病患者的 LHRHR 表达水平，特别是在某些卵巢部位可能明显较低，这可能影响新的靶向治疗方案的使用。对继发性 Müllerian 系统部位及其激素受体状态的研究对于理解 LHRH 杂交分子抗癌治疗疗效缺乏的机制可能至关重要。
